Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Abeona Therapeutics (ABEO)

Abeona Therapeutics (ABEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,156
  • Shares Outstanding, K 146,950
  • Annual Sales, $ 3,000 K
  • Annual Income, $ -84,940 K
  • 60-Month Beta 1.25
  • Price/Sales 10.19
  • Price/Cash Flow N/A
  • Price/Book 0.97
Trade ABEO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.56
  • Most Recent Earnings -0.10 on 05/13/22
  • Next Earnings Date 07/27/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 682.67% ( +221.82%)
  • Historical Volatility 80.22%
  • IV Percentile 84%
  • IV Rank 46.99%
  • IV High 1,334.47% on 02/10/22
  • IV Low 104.97% on 03/16/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 16
  • Volume Avg (30-Day) 22
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 2,656
  • Open Int (30-Day) 4,175

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +68.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1515 +26.47%
on 06/17/22
0.2132 -10.13%
on 06/29/22
+0.0365 (+23.53%)
since 06/01/22
3-Month
0.1303 +47.05%
on 05/11/22
0.3742 -48.80%
on 04/05/22
-0.1311 (-40.63%)
since 04/01/22
52-Week
0.1303 +47.05%
on 05/11/22
1.6000 -88.03%
on 07/02/21
-1.3584 (-87.64%)
since 07/01/21

Most Recent Stories

More News
Pfizer (PFE) Discloses Autoimmune Drug Deal With Priovant

Pfizer (PFE) announces the name of the new company that it formed with its partner, Roivant Sciences (ROIV), to develop and market its dual TYK2/JAK1 inhibitor.

PFE : 52.31 (-0.23%)
ABEO : 0.1916 (-7.88%)
SESN : 0.7989 (-1.42%)
ROIV : 4.42 (+8.60%)
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm

Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.

ALKS : 30.53 (+2.48%)
ABEO : 0.1916 (-7.88%)
SESN : 0.7989 (-1.42%)
FSTX : 6.30 (+0.56%)
Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug

Acer Therapeutics' (ACER) new drug application for ACER-001 to treat urea cycle disorders faces rejection from the FDA. Share price falls 21% following the announcement.

ALKS : 30.53 (+2.48%)
ABEO : 0.1916 (-7.88%)
ACER : 1.2800 (+1.59%)
SESN : 0.7989 (-1.42%)
ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids

ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.

ALKS : 30.53 (+2.48%)
ABEO : 0.1916 (-7.88%)
OBSV : 1.7600 (+9.32%)
SESN : 0.7989 (-1.42%)
Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study

Clovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical utility of FAP-2286, its targeted radiotherapy candidate, as a treatment for advanced solid tumors.

ALKS : 30.53 (+2.48%)
CLVS : 2.85 (+58.33%)
ABEO : 0.1916 (-7.88%)
SESN : 0.7989 (-1.42%)
FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy

An FDA advisory committee favors approval for bluebird bio's (BLUE) beti-cel to treat transfusion-dependent thalassemia. A final decision by the regulatory body is expected on Aug 19, 2022.

ALKS : 30.53 (+2.48%)
BLUE : 4.28 (+3.38%)
ABEO : 0.1916 (-7.88%)
SESN : 0.7989 (-1.42%)
FDA Committee Recommends bluebird's (BLUE) CALD Therapy

An FDA advisory committee supports approving bluebird bio's (BLUE) eli-cel for treating cerebral adrenoleukodystrophy. NASDAQ halts trading BLUE's common stock on Jun 9 and 10.

ALKS : 30.53 (+2.48%)
BLUE : 4.28 (+3.38%)
ABEO : 0.1916 (-7.88%)
SESN : 0.7989 (-1.42%)
bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy

Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.

ALKS : 30.53 (+2.48%)
BLUE : 4.28 (+3.38%)
ABEO : 0.1916 (-7.88%)
SESN : 0.7989 (-1.42%)
AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half

Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients....

AZN : 65.95 (-0.18%)
ALKS : 30.53 (+2.48%)
ABEO : 0.1916 (-7.88%)
SESN : 0.7989 (-1.42%)
Abeona Therapeutics to Present at the Jefferies Healthcare Conference

NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy,...

ABEO : 0.1916 (-7.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

See More

Key Turning Points

3rd Resistance Point 0.2227
2nd Resistance Point 0.2139
1st Resistance Point 0.2027
Last Price 0.1916
1st Support Level 0.1827
2nd Support Level 0.1739
3rd Support Level 0.1627

See More

52-Week High 1.6000
Fibonacci 61.8% 1.0386
Fibonacci 50% 0.8652
Fibonacci 38.2% 0.6917
Last Price 0.1916
52-Week Low 0.1303

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar